Inclisrian statin dyslipidemia
Atherosclerotic cardiovascular disease (ASCVD)
Up-to-date pharmacological topics for inclisiran and statin for dyslipidemia are described. The efficacy of inclisiran has been reported for reduction of LDL-C values. Inclisiran has been involved in gene silencing, which brings selective inhibition of a protein by targeting its mRNA. For RCTs of inclisiran, ORION 10/11 studies were conducted, where inclisiran and control groups were followed 1.5 years. LDL-C reduced in 53.8%/49.2%. RCTs of 19 meta-analyses showed whether statins will prolong life and its degree. As a result, statin can delay onset of events compared to placebo for cardiovascular death 9.3 days, myocardial infarction 18 days, and stroke 6.1 days.
SunText Review of Endocrine Care
This is an open-access article distributed under the terms of the Creative Commons Attribution License(https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
|DOI (Published Version)|
srec_1_1_104.pdf 341 KB